Challenges in managing endocrine and metabolic dysfunction in a child with Prader–Willi syndrome and medulloblastoma Authors: Daniel Chan, Harshini Katugampola, Mehul T Dattani Published: 2026 ABSTRACT AbstractPrader–Willi syndrome (PWS) is a complex genetic disorder characterized by severe hyperphagia, early-onset obesity, developmental delay, behavioral disturbances, and multiple endocrine dysfunctions. Clinical management is especially challenging when complicated by central nervous system tumors, which can further exacerbate hypothalamic dysfunction with consequent endocrine and metabolic complications. We present a clinically complex case of a girl with genetically confirmed PWS who developed medulloblastoma, requiring neurosurgical resection, craniospinal radiotherapy, and chemotherapy. Subsequent management was complicated by severe obesity, insulin resistance with impaired glucose tolerance, central hypothyroidism, adrenal insufficiency, and progressive neurological decline with severe obstructive sleep apnea. Key clinical challenges highlighted include the cautious re-initiation of growth hormone therapy post-oncological treatment, carefully balancing its metabolic and growth benefits, alongside multidisciplinary strategies to manage severe obesity-related endocrine and metabolic dysfunction. This case describes the co-existence of PWS and medulloblastoma, highlighting important clinical considerations that may inform management strategies and optimize outcomes in similarly complex situations. Introduction Prader–Willi syndrome (PWS) is a complex genetic disorder arising from the absence of expression of paternally inherited genes on chromosome 15q11-q13 [1]. Central to the pathophysiology of PWS is hypothalamic dysfunction, which underpins its hallmark clinical manifestations, including severe hyperphagia, early-onset obesity, developmental delay, behavioral abnormalities, and multiple endocrine disturbances such as growth hormone deficiency, secondary hypogonadism, and secondary hypothyroidism [2]. Growth hormone (GH) therapy, a cornerstone of PWS management, significantly improves linear growth, body composition, and metabolic outcomes. Given these complex hypothalamic disturbances, optimal management of PWS necessitates a coordinated, multidisciplinary approach involving endocrinologists, dietitians, psychologists, and sleep specialists to effectively address the multifaceted clinical needs [3]. Severe obesity has been associated with an increased risk of malignancy through proposed mechanisms involving chronic inflammation, insulin resistance, altered adipokine secretion, and dysregulated insulin-like growth factor-1 (IGF-1) signaling [4]. This is particularly relevant to PWS, in which severe obesity is a hallmark clinical feature. However, data specifically addressing malignancy risks in patients with PWS remain sparse and inconsistent, although recent evidence indicates a potentially higher malignancy risk specifically associated with the paternal deletion genetic subtype of PWS [5]. Although GH therapy, when indicated, is generally considered safe and beneficial, its use in patients with a prior history of malignancy is approached cautiously. We present a clinically challenging case of a patient with genetically confirmed PWS complicated by the development of a medulloblastoma. This case highlights important clinical considerations, including managing GH therapy in a child with a previous history of malignancy. Additionally, it examines the complex management issues related to severe obesity and metabolic disturbances in patients with PWS following oncological treatment. Current literature and guidelines provide limited guidance on these multifaceted management issues, underscoring the necessity for individualized care, multidisciplinary strategies, and rigorous long-term surveillance. By presenting this case, we aim to illustrate key challenges in clinical decision-making and provide valuable insights into managing these complexities. Case presentation Our patient presented at age 4 years to the pediatric endocrine clinic on a background of PWS, with a de novo deletion identified on the paternally inherited chromosome 15. At presentation, her height was 101.5 cm (Z-score: 0.17), weight was 26 kg (Z-score: 2.87), and body mass index was markedly elevated at 25.2 kg/m2 (Z-score: 3.76), plotted on the United Kingdom-World Health Organization (UK-WHO) growth chart for girls aged 2-20 years (Fig. 1). She was prepubertal on Tanner staging. Additional clinical features included developmental delay, with significant impairments in speech and language, motor milestones, and cognition. Behavioral disturbances included hyperphagia, frequent temper tantrums, aggressive outbursts, and obsessive-compulsive traits. She also had severe obstructive sleep apnea (OSA), necessitating nocturnal continuous positive airway pressure (CPAP) therapy. She was assessed to have GH deficiency with a poor height velocity of 3.5 cm/year (Z-score <−2.0). Baseline endocrine evaluation did not demonstrate additional pituitary hormone deficiencies, and there was no documented evidence of dysglycemia or insulin resistance. Hence, growth hormone therapy was initiated at a dose of 0.4 mg nightly (approximately 15 µg/kg/day), with IGF-1 levels maintained between 0 and +1 standard deviation score (SDS) during treatment. She responded well to the GH treatment with an increase in height velocity to 13.5 cm/year (Z-score >2.0), and an increase in her height standard deviation score from 0.17 to 0.84. Growth chart showing the patient's height (A) and weight (B) trajectories, plotted on UK-WHO growth standards. Green arrows indicate initiation of growth hormone therapy; red arrows indicate discontinuation of growth hormone therapy; blue arrows indicate initiation of hydrocortisone and levothyroxine replacement; black arrow indicates patient's mid-parental height. At age 7 years, she presented acutely to the emergency department with symptoms indicative of raised intracranial pressure, including severe headaches, recurrent vomiting, and gait instability. Urgent magnetic resonance imaging (MRI) revealed a posterior fossa tumor (Fig. 2). GH therapy was immediately discontinued. She underwent craniotomy with complete macroscopic excision of the tumor. Histopathology confirmed medulloblastoma. Postoperatively, she underwent craniospinal radiotherapy (total dose of 23.5 Gy, with a posterior fossa boost to 54 Gy), followed by chemotherapy according to the Primitive Neuroectodermal Tumor 2004 protocol. Chemotherapy initially consisted of cisplatin, vincristine, and lomustine; cisplatin was subsequently replaced with carboplatin due to impaired renal function. Axial (left) and coronal (right) magnetic resonance imaging demonstrating a partly solid, partly cystic, enhancing posterior fossa tumor (indicated by white arrows) extending into the left foramen of Luschka, causing anterior displacement of the pons and medulla. Diagnostic assessment Following completion of oncological treatment, the patient exhibited marked deterioration in endocrine and metabolic status, with rapidly worsening obesity, significant weight gain, and poor linear growth (Fig. 1). Endocrine evaluation (Table 1) revealed persistently low IGF-1 concentrations (35 ng/mL [SI: 4.6 nmol/L]; normal range 74-388 ng/mL [SI: 9.7-50.7]), consistent with severe GH deficiency. GH deficiency was confirmed through glucagon stimulation testing, with all growth hormone concentrations <0.1 ng/mL (SI: <0.1 μg/mL). Central hypothyroidism was demonstrated by a low free thyroxine level with an inappropriately normal thyroid-stimulating hormone concentration (free thyroxine 0.82 ng/dL [SI: 10.5 pmol/L], normal range 0.93-1.71 ng/dL [SI: 12-22 pmol/L]; thyroid-stimulating hormone 0.8 µIU/mL [SI: 0.8 mU/L], normal range 0.4-4.0 µIU/mL [SI: 0.4-4.0 mU/L]). Adrenal insufficiency was evident by 24-hour cortisol profiling prior to initiation of hydrocortisone, with a mean cortisol concentration of <5.4 µg/dL (SI: <150 nmol/L) [6], and an inadequate peak cortisol of 13.7 µg/dL (SI: 378 nmol/L) on a standard dose Synacthen test (Table 2). Table 1Results of pituitary function tests (following treatment for medulloblastoma)Conventional unitsSI unitsFree T40.82 ng/dL(0.93-1.71 ng/dL)10.5 pmol/L(12-22 pmol/L)TSH0.8 μIU/mL(0.4-4.0 μIU/mL)0.8 mU/L(0.4-4.0 mU/L)FSH<0.2 mIU/mL<0.2 IU/LLH<0.2 mIU/mL<0.2 IU/LProlactin170 mU/L(128-702 mU/L)8.0 μg/L(6.0-33.0 μg/L)IGF-135 ng/mL(74-388 ng/mL)4.6 nmol/L(9.7-50.7 nmol/L)IGFBP33.19 mg/L(1.8-7.1 mg/L)3.19 μg/mL(1.8-7.1 μg/mL)ACTH (8am)13 ng/L(5-49 ng/L)2.86 pmol/L(1.1-10.8 pmol/L)Cortisol (8am)3.2 μg/dL88 nmol/LAbbreviations: ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; IGF-1, insulin-like growth factor-1; IGFBP3, insulin-like growth factor-binding protein 3; LH, luteinizing hormone; T4, thyroxine; TSH, thyroid stimulating hormone. Results of pituitary function tests (following treatment for medulloblastoma) Abbreviations: ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; IGF-1, insulin-like growth factor-1; IGFBP3, insulin-like growth factor-binding protein 3; LH, luteinizing hormone; T4, thyroxine; TSH, thyroid stimulating hormone. Table 2Twenty-four-hour cortisol profiling, indicating adrenal insufficiency with mean cortisol level <5.4 µg/dL (SI: <150 nmol/L)Cortisol profile (time)10:0012:0014:0016:0018:0020:0022:000:002:004:006:008:0010:00Cortisol(SI units)125 nmol/L98 nmol/L98 nmol/L29 nmol/L102 nmol/L66 nmol/L<28 nmol/L28 nmol/L203 nmol/L232 nmol/L146 nmol/L88 nmol/L109 nmol/LCortisol(Conventional units)4.54 µg/dL3.56 µg/dL3.56 µg/dL1.05 µg/dL3.70 µg/dL2.40 µg/dL<1.02 µg/dL1.02 µg/dL7.37 µg/dL8.42 µg/dL5.30 µg/dL3.19 µg/dL3.96 µg/dL Twenty-four-hour cortisol profiling, indicating adrenal insufficiency with mean cortisol level <5.4 µg/dL (SI: <150 nmol/L) An oral glucose tolerance test revealed significant insulin resistance and impaired glucose tolerance (2-hour post-prandial glucose: 155 mg/dL [SI: 8.6 mmol/L], insulin >43.2 µIU/mL [SI: 300 mU/L]). Glycosylated hemoglobin (HbA1c) was also elevated at 6.4% (SI: 46 mmol/mol) (normal range 4.0-6.0% [SI: 20-42 mmol/mol]). A polysomnography revealed a significantly elevated obstructive apnea–hypopnea index (OAHI) of 38.2 events per hour, in keeping with severe OSA. CPAP therapy was recommended at a pressure of 10 cm H2O. Serial neuroimaging with MRI conducted regularly demonstrated no tumor recurrence initially. Further assessment documented visual impairment associated with bilateral subcapsular cataracts and optic nerve pallor, alongside progressive bilateral sensorineural hearing loss attributed to previous craniospinal irradiation and chemotherapy treatment. Treatment Endocrine management involved levothyroxine replacement therapy, titrated up to 100 mcg daily to achieve euthyroidism, and hydrocortisone replacement (5 mg morning, 5 mg midday, and 2.5 mg evening), with instructions provided for stress dosing during illness or physiological stress. Given profound GH deficiency, persistent poor linear growth, and significant metabolic derangements, GH treatment was cautiously recommenced at a dose of 0.6 mg nightly (approximately 18 mcg/kg/day) following multidisciplinary discussion. Management of severe OSA was critical; CPAP therapy at 10 cm H2O was strongly recommended, although compliance remained notably poor despite extensive reinforcement due to neurocognitive and behavioral challenges. Metformin therapy was initiated at 250 mg twice daily and subsequently increased to 250 mg 3 times daily in response to insulin sensitivity and severe obesity. Comprehensive lifestyle management strategies were implemented, involving structured dietary advice, caloric restriction, behavioral support, and increased physical activity. This multidisciplinary approach involved dietetics, physiotherapy, psychology, and endocrine teams. Outcome and follow-up Following completion of oncological treatment, she remained under regular oncology follow-up with outpatient clinical review and surveillance MRI, initially at 3-monthly intervals and subsequently at 6-monthly intervals. Surveillance imaging remained reassuring initially, with no evidence of recurrence. However, at approximately 10 years of age, nearly 3 years following completion of oncological treatment, the patient re-presented acutely with new neurological symptoms, including right-sided hemiparesis, facial palsy, dysphagia, dysarthria, and marked ataxia. Urgent repeat MRI demonstrated a new enhancing pontine lesion suggestive of recurrent medulloblastoma (Fig. 3). Biopsy confirmed tumor recurrence. GH therapy was discontinued, and palliative chemotherapy with temozolomide and celecoxib was initiated. High-dose dexamethasone initially provided symptomatic relief; however, re-irradiation was not feasible due to the high risk of radionecrosis and edema. Sagittal (left) and coronal (right) magnetic resonance imaging sequences demonstrating enhancing lesions (indicated by white arrows) in the left aspect of the pons and left medullary pyramid, consistent with recurrence of medulloblastoma. She subsequently experienced progressive neurological deterioration characterized by severe autonomic instability, worsening bulbar dysfunction, profound weakness, and complete dysphagia. Intensive supportive and palliative care was provided, ensuring symptomatic comfort and quality of life. She remained comfortable, without significant pain, until she passed away aged 10.6 years old, approximately 6 years following her initial endocrine presentation, secondary to complications from progressive recurrent pontine medulloblastoma. This case highlights the considerable challenges involved in managing severe endocrine disorders, profound metabolic complications, and significant neurological sequelae in patients with PWS. It underscores the critical importance of integrated, multidisciplinary care and rigorous long-term surveillance in managing the complex interplay of endocrinological, neurological, and oncological conditions in such patients. Discussion Malignancies are generally uncommon among individuals with PWS, with recent large cohort studies reporting a prevalence of approximately 0.8% in the pediatric age groups [5]. However, specific malignancies may occur at higher frequencies in this patient population, notably myeloid leukemias and gonadal tumors [7, 8]. Medulloblastoma has rarely been described in patients with PWS, and its occurrence in this case highlights important endocrine and metabolic management challenges, particularly in relation to GH therapy. Recent evidence indicates a potential association between malignancy risk and the paternal deletion subtype of PWS [5]. Despite the overall rarity, clinicians should remain vigilant due to atypical presentations in PWS resulting from their characteristically high pain threshold and cognitive impairment. Although routine screening beyond general population recommendations is currently not indicated, participation in national cancer screening programs should be encouraged given possible obesity-related cancer risks inherent to PWS as well [9]. GH therapy represents a cornerstone in the management of PWS, demonstrating clear benefits for muscle tone, linear growth, body composition, and metabolic health [10]. Despite the known mitogenic potential of GH and IGF-1, current evidence does not support a significantly increased risk of tumor recurrence in pediatric cancer survivors, including those previously treated for central nervous system tumors [11, 12]. A meta-analysis by Wang et al [13]. indicated that GH therapy in pediatric brain tumor survivors was not associated with an increased risk of tumor recurrence. Although recurrence rates appeared lower in patients who received GH therapy than in those who did not (21.0% vs 44.3%), this finding should be interpreted cautiously given the observational nature of the included studies and the potential for residual confounding. Nevertheless, there have been reports of a slightly elevated risk of secondary neoplasms, especially meningiomas, in childhood cancer survivors treated long-term with GH therapy [14, 15]. Hence, ongoing surveillance and individualized risk–benefit assessments remain essential, particularly in patients with a previous malignancy. Severe obesity, a prominent clinical feature in PWS, contributes substantially to metabolic complications. Pediatric cancer survivors already frequently face heightened risks of metabolic syndrome and endocrine dysfunction secondary to hypothalamic–pituitary axis disruption from oncological therapies [16, 17]. For patients with PWS, these risks may be further exacerbated, resulting in severe insulin resistance, impaired glucose tolerance, hypothyroidism, and adrenal insufficiency [18]. Given the profound impact on quality of life and morbidity, comprehensive multidisciplinary management, including dietary interventions, structured behavioral therapy, and pharmacological agents such as metformin, becomes critical in addressing these complex metabolic disturbances [10, 19]. Emerging evidence supports obesity as an independent risk factor for various malignancies, potentially mediated through mechanisms involving chronic inflammation, insulin resistance, abnormal adipokine secretion, and altered IGF-1 signaling pathways [4, 9]. Childhood and adolescent obesity has been linked to increased cancer incidence in adulthood, emphasizing its role as a critical modifiable risk factor [20, 21]. Although causal pathways remain complex and multifactorial, the strong epidemiological associations highlight the importance of early obesity interventions as potential strategies to mitigate malignancy risks. This is especially pertinent in PWS patients, whose inherent hypothalamic dysfunction and hyperphagia predispose them to severe obesity [22]. Proactive obesity management strategies implemented early in life may therefore substantially improve long-term health outcomes in this vulnerable population. In conclusion, our case underscores the complex management challenges encountered in a patient with PWS complicated by malignancy, multiple endocrinopathies, and severe metabolic dysfunction. It emphasizes the essential role of proactive multidisciplinary care, incorporating vigilant endocrine monitoring, comprehensive metabolic management, and rigorous long-term surveillance. Finally, we hope that insights derived from this case will provide valuable guidance to inform clinical decision-making and optimize patient outcomes in similarly complex patient populations. Learning points The presence of metabolic dysfunction and multiple endocrinopathies in patients with PWS, including severe GH deficiency, central hypothyroidism, adrenal insufficiency, and hypothalamic obesity, presents significant clinical management challenges, necessitating comprehensive, individualized, and multidisciplinary management strategies. The presence of metabolic dysfunction and multiple endocrinopathies in patients with PWS, including severe GH deficiency, central hypothyroidism, adrenal insufficiency, and hypothalamic obesity, presents significant clinical management challenges, necessitating comprehensive, individualized, and multidisciplinary management strategies. Current evidence suggests that GH therapy does not increase the risk of tumor recurrence in pediatric cancer survivors; on the other hand, GH therapy offers important benefits for growth and metabolic health. Current evidence suggests that GH therapy does not increase the risk of tumor recurrence in pediatric cancer survivors; on the other hand, GH therapy offers important benefits for growth and metabolic health. Managing severe obesity-related metabolic dysfunctions, including insulin resistance and dysglycemia, is particularly challenging in patients with PWS. They are inherently vulnerable due to underlying hypothalamic dysfunction and risk of developing multiple endocrinopathies. This underscores the pressing need for proactive, multidisciplinary interventions. Effective management requires a multi-pronged approach with structured dietary strategies, behavioral therapies, and targeted pharmacological treatments to optimize patient outcomes. Managing severe obesity-related metabolic dysfunctions, including insulin resistance and dysglycemia, is particularly challenging in patients with PWS. They are inherently vulnerable due to underlying hypothalamic dysfunction and risk of developing multiple endocrinopathies. This underscores the pressing need for proactive, multidisciplinary interventions. Effective management requires a multi-pronged approach with structured dietary strategies, behavioral therapies, and targeted pharmacological treatments to optimize patient outcomes. Recent evidence indicates that even though malignancies are uncommon in PWS, certain tumor types such as myeloid leukemias and gonadal tumors may occur more frequently, particularly in children with the paternal deletion subtype. Clinicians should maintain an index of suspicion in the presence of abnormal signs on physical examination, as presentations may be atypical due to cognitive impairment and altered pain sensitivity in children with PWS. Recent evidence indicates that even though malignancies are uncommon in PWS, certain tumor types such as myeloid leukemias and gonadal tumors may occur more frequently, particularly in children with the paternal deletion subtype. Clinicians should maintain an index of suspicion in the presence of abnormal signs on physical examination, as presentations may be atypical due to cognitive impairment and altered pain sensitivity in children with PWS. Contributors All authors made contributions to authorship. M.T.D. and H.K. contributed to the conception and design of the work. D.C. and H.K. contributed to the acquisition, analysis, and interpretation of clinical data. H.K. and M.T.D. were involved in the diagnosis and clinical management of the patient. D.C. drafted the manuscript. D.C., H.K., and M.T.D. critically reviewed and revised the manuscript for important intellectual content. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work.